

## Dimepamypa

1. Wang T.J. Natural history of asymptomatic left ventricular systolic dysfunction in the community. *Circulation* 2003; 108: 977-982.
2. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. *N Engl J Med* 1992; 327: 685-691.
3. Butler J., Fonarow G.C., Zile M.R., Lam C.S., Roessig L., Schelbert E.B., Shah S.J., Ahmed A., Bonow R.O., Cleland J.G.F., Cody R.J., Chioncel O., Collins S.P., Dunnmon P., Filippatos G., Lefkowitz M.P., Marti C.N., McMurray J.J., Misselwitz F., Nodari S., O'Connor C., Pfeffer M.A., Pieske B., Pitt B., Rosano G., Sabbah H.N., Senni M., Solomon S.D., Stockbridge N., Teerlink J.R., Georgiopoulou V.V., Gheorghiade M. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. *JACC Heart Fail* 2014; 2: 97-112.
4. Ponikowski P. (Chairperson) (Poland), Voors A.A. (Co-Chairperson) (The Netherlands), Anker S.D. (Germany), Bueno H. (Spain), Cleland J.G.F. (UK), Coats A.J.S. (UK), Falk V. (Germany), Gonzalez-Juanatey J.-R. (Spain), Harjola V.-P. (Finland), Jankowska E.A. (Poland), Jessup M. (USA), Linde C. (Sweden), Nihoyannopoulos P. (UK), Parissis J.T. (Greece), Pieske B. (Germany), Riley J.P. (UK), Rosano G.M.C. (UK/Italy), Ruilope L.M. (Spain), Ruschitzka F. (Switzerland), Rutten F.H. (The Netherlands), van der Meer P. (The Netherlands), Authors/Task Force Members and Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA). *European Heart Journal* 2016; 37 (27): 2129-2200.
5. McMurray J.J.V. Clinical practice. Systolic heart failure. *N Engl J Med* 2010; 3623: 228-238.
6. Chen J., Normand S.-L.T., Wang Y., Krumholz H.M. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. *JAMA* 2011; 306: 1669-1678.
7. Dunlay S.M., Redfield M.M., Weston S.A., Therneau T.M., Hall Long K., Shah N.D., Roger V.L. Hospitalizations after heart failure diagnosis a community perspective. *J Am Coll Cardiol* 2009; 54: 1695-1702.
8. Mosterd A., Hoes A.W. Clinical epidemiology of heart failure. *Heart* 2007; 93: 1137-1146.
9. Redfield M.M., Jacobsen S.J., Burnett J.C., Mahoney D.W., Bailey K.R., Rodeheffer R.J. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. *JAMA* 2003; 289: 194-202.
10. Bleumink G.S., Knetsch A.M., Sturkenboom M.C.J.M., Straus S.M.J.M., Hofman A., Deckers J.W., Witteman J.C.M., Stricker B.H.C. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. *Eur Heart J England*; 2004; 25: 1614-1619.
11. Ceia F., Fonseca C., Mota T., Morais H., Matias F., De Sousa A., Oliveira A.G. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. *Eur J Heart Fail* 2002; 4: 531-539.
12. van Riet E.E.S., Hoes A.W., Limburg A., Landman M.A.J., van der Hoeven H., Rutten F.H. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. *Eur J Heart Fail* 2014; 16: 772-777.
13. Filippatos G., Parissis J.T. Heart failure diagnosis and prognosis in the elderly: the proof of the pudding is in the eating. *Eur J Heart Fail* 2011; 13: 467-471.
14. Rutten F.H., Cramer M.-J.M., Grobbee D.E., Sachs A.P.E., Kirkels J.H., Lammers J.-W.J., Hoes A.W. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. *Eur Heart J* 2005; 26: 1887-1894.
15. Boonman-de Winter L.J.M., Rutten F.H., Cramer M.J.M., Landman M.J., Liem A.H., Rutten G.E.H.M., Hoes A.W. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. *Diabetologia* 2012; 55: 2154-2162.
16. van Riet E.E.S., Hoes A.W., Wagenaar K.P., Limburg A., Landman M.A.J., Rutten F.H. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. *Eur J Heart Fail* 2016.
17. Abhayaratna W.P., Smith W.T., Becker N.G., Marwick T.H., Jeffery I.M., McGill D.A. Prevalence of heart failure and systolic ventricular dysfunction in older Australians: the Canberra Heart Study. *Med J Aust* 2006; 184: 151-154.
18. Tiller D., Russ M., Greiser K.H., Nuding S., Ebel H., Kluttig A., Kors J.A., Thiery J., Bruegel M., Haerting J., Werdan K. Prevalence of symptomatic heart failure with reduced and with normal ejection fraction in an elderly general population – the CARLA study. *PLoS One* 2013; 8: e59225.
19. Mureddu G.F., Agabiti N., Rizzello V., Forastiere F., Latini R., Cesaroni G., Masson S., Cacciatori G., Colivicchi F., Ugucioni M., Perucci C.A., Bocconelli A. Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy. *Eur J Heart Fail* 2012; 14: 718-729.
20. Badano L.P., Albanese M.C., De Biaggio P., Rozbowski P., Miani D., Fresco C., Fioretti P.M. Prevalence, clinical characteristics, quality of life, and prognosis of patients with congestive heart failure and isolated left ventricular diastolic dysfunction. *J Am Soc Echocardiogr* 2004; 17: 253-261.
21. Philbin E.F., Rocco T.A., Lindenmuth N.W., Ulrich K., Jenkins P.L. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. *Am J Med* 2000; 109: 605-613.
22. Magana-Serrano J.A., Almahmeed W., Gomez E., Al-Shamiri M., Adgar D., Sosner P., Herpin D. Prevalence of heart failure with preserved ejection fraction in Latin American, Middle Eastern, and North African Regions in the I-PREFER study (Identification of Patients With Heart Failure and PREServed Systolic Function: an epidemiological regional study). *Am J Cardiol* 2011; 108: 1289-1296.
23. Peyster E., Norman J., Domanski M. Prevalence and predictors of heart failure with preserved systolic function: community hospital admissions of a racially and gender diverse elderly population. *J Card Fail* 2004; 10: 49-54.
24. Hellermann J.P., Jacobsen S.J., Reeder G.S., Lopez-Jimenez F., Weston S.A., Roger V.L. Heart failure after myocardial infarction: prevalence of preserved left ventricular systolic function in the community. *Am Heart J* 2003; 145: 742-748.
25. Maggioni A.P., Dahlstrom U., Filippatos G., Chioncel O., Leiro M.C., Drozd J., Fruhwald F., Gullestad L., Logeart D., Fabbri G., Urso R., Metra M., Parissis J., Persson H., Ponikowski P., Rauchhaus M., Voors A.A., Nielsen O.W., Zannad F., Tavazzi L., Crespo-Leiro M. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). *Eur J Heart Fail* 2013; 15: 808-817.
26. Davie P., Francis C.M., Caruana L., Sutherland G.R., McMurray J.J. Assessing diagnosis in heart failure: which features are any use? *QJM* 1997; 90: 335-339.
27. Mant J., Doust J., Roalfe A., Barton P., Cowie M.R., Glasziou P., Mant D., McManus R.J., Holder R., Deeks J., Fletcher K., Qume M., Sohanpal S., Sanders S., Hobbs F.D.R. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. *Health Technol Assess* 2009; 13: 1-207, iii.
28. Oudejans I., Mosterd A., Bloemen J.A., Valk M.J., van Velzen E., Wielders J.P., Zuithoff N.P., Rutten F.H., Hoes A.W. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. *Eur J Heart Fail* 2011; 13: 518-527.
29. Fonseca C. Diagnosis of heart failure in primary care. *Heart Fail Rev* 2006; 11: 95-107.
30. Kelder J.C., Cramer M.J., van Wijngaarden J., van Tooren R., Mosterd A., Moons K.G.M., Lammers J.W., Cowie M.R., Grobbee D.E., Hoes A.W. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. *Circulation* 2011; 124: 2865-2873.
31. Boonman-de Winter L.J.M., Rutten F.H., Cramer M.J., Landman M.J., Zuithoff N.P.A., Liem A.H., Hoes A.W. Efficiently screening heart failure in patients with type 2 diabetes. *Eur J Heart Fail* 2015; 17: 187-195.
32. Rutten F.H., Moons K.G.M., Cramer M.-J.M., Grobbee D.E., Zuithoff N.P.A., Lammers J.-W.J., Hoes A.W. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. *BMJ* 2005; 331: 1379.
33. Hawkins N.M., Petrie M.C., Jhund P.S., Chalmers G.W., Dunn F.G., McMurray J.J.V. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. *Eur J Heart Fail* 2009; 11: 130-139.
34. Daniels L.B., Clopton P., Bhalla V., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P., Omland T., Storrow A.B., Abraham W.T., Wu A.H.B., Steg P.G., Westheim A., Knudsen C.W., Perez A., Kazanegra R., Herrmann H.C., McCullough P.A., Maisel A.S. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. *Am Heart J* 2006; 151: 999-1005.
35. Wong C.M., Hawkins N.M., Jhund P.S., MacDonald M.R., Solomon S.D., Granger C.B., Yusuf S., Pfeffer M.A., Swedberg K., Petrie M.C., McMurray J.J.V. Clinical characteristics and outcomes of young and very young adults with heart failure: the CHARM program (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). *J Am Coll Cardiol* 2013; 62: 1845-1854.
36. Wong C.M., Hawkins N.M., Petrie M.C., Jhund P.S., Gardner R.S., Ariti C.A., Poppe K.K., Earle N., Whalley G.A., Squire I.B., Doughty R.N., McMurray J.J.V. Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). *Eur Heart J* 2014; 35: 2714-2721.
37. Dokainish H., Nguyen J.S., Bobek J., Goswami R., Lakkis N.M. Assessment of the American Society of Echocardiography-European Association of Echocardiography guidelines for diastolic function in patients with depressed ejection fraction: an echocardiographic and invasive haemodynamic study. *Eur J Echocardiogr* 2011; 12: 857-864.
38. Nagueh S.F., Bhatt R., Vivo R.P., Krim S.R., Sarvari S.I., Russell K., Edvardsen T., Smiseth O.A., Estep J.D. Echocardiographic evaluation of hemodynamics in patients with decompensated systolic heart failure. *Circ Cardiovasc Imaging* 2011; 4: 220-227.

- Voigt J.-U., Pedrizzetti G., Lysyansky P., Marwick T.H., Houle H., Baumann R., Pedri S., Ito Y., Abe Y., Metz S., Song J.H., Hamilton J., Sengupta P.P., Kolias T.J., d'Hooge J., Aurigemma G.P., Thomas J.D., Badano L.P. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. *Eur Heart J Cardiovasc Imaging* 2015; 16: 1-11.
40. Paulus W.J., Tschope C., Sanderson J.E., Rusconi C., Flachskampf F.A., Rademakers F.E., Marino P., Smiseth O.A., De Keulenaer G., Leite-Moreira A.F., Borbely A., Edes I., Handoko M.L., Heymans S., Pezzali N., Pieske B., Dickstein K., Fraser A.G., Brutsaert D.L. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. *Eur Heart J* 2007; 28: 2539-2550.
  41. Borlaug B.A., Paulus W.J. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. *Eur Heart J* 2011; 32: 670-679.
  42. Lang R.M., Badano L.P., Mor-Avi V., Afilalo J., Armstrong A., Ernande L., Flachskampf F.A., Foster E., Goldstein S.A., Kuznetsova T., Lancellotti P., Muraru D., Picard M.H., Rietzschel E.R., Rudski L., Spencer K.T., Tsang W., Voigt J.-U. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 2015; 16: 233-270.
  43. Caballero L., Kou S., Dulgheru R., Gonjilashvili N., Athanassopoulos G.D., Barone D., Baroni M., Cardim N., Gomez de Diego J.J., Oliva M.J., Hagendorff A., Hristova K., Lopez T., Magne J., Martinez C., de la Morena G., Popescu B.A., Penicka M., Ozyigit T., Rodrigo Carbonero J.D., Salustri A., Van De Veire N., Von Bardeleben R.S., Vinereanu D., Voigt J.-U., Zamorano J.L., Bernard A., Donal E., Lang R.M., Badano L.P., Lancellotti P. Echocardiographic reference ranges for normal cardiac Doppler data: results from the NORRE Study. *Eur Heart J Cardiovasc Imaging* 2015; 16: 1031-1041.
  44. Cohen G.I., Pietrolungo J.F., Thomas J.D., Klein A.L. A practical guide to assessment of ventricular diastolic function using Doppler echocardiography. *J Am Coll Cardiol* 1996; 27: 1753-1760.
  45. Gilman G., Nelson T.A., Hansen W.H., Khandheria B.K., Ommen S.R. Diastolic function: a sonographer's approach to the essential echocardiographic measurements of left ventricular diastolic function. *J Am Soc Echocardiogr* 2007; 20: 199-209.
  46. Nagueh S.F., Appleton C.P., Gillebert T.C., Marino P.N., Oh J.K., Smiseth O.A., Waggoner A.D., Flachskampf F.A., Pellikka P.A., Evangelisa A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. *Eur J Echocardiogr* 2009; 10: 165-193.
  47. Nishimura R.A., Appleton C.P., Redfield M.M., Ilstrup D.M., Holmes D.R., Tajik A.J. Noninvasive doppler echocardiographic evaluation of left ventricular filling pressures in patients with cardiomyopathies: a simultaneous Doppler echocardiographic and cardiac catheterization study. *J Am Coll Cardiol* 1996; 28: 1226-1233.
  48. Ommen S.R., Nishimura R.A., Appleton C.P., Miller F.A., Oh J.K., Redfield M.M., Tajik A.J. Clinical utility of Doppler echocardiography and tissue doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler catheterization study. *Circulation* 2000; 102: 1788-1794.
  49. Thomas J.T., Kelly R.F., Thomas S.J., Stamos T.D., Albasha K., Parrillo J.E., Calvin J.E. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. *Am J Med* 2002; 112: 437-445.
  50. Sicari R., Nihoyannopoulos P., Evangelista A., Kasprzak J., Lancellotti P., Poldermans D., Voigt J.U., Zamorano J.L. Stress Echocardiography Expert Consensus Statement-Executive Summary: European Association of Echocardiography (EAE) (a registered branch of the ESC). *Eur Heart J* 2009; 30: 278-289.
  51. Garnier F., Eicher J.-C., Jazayeri S., Bertaux G., Bouchot O., Aho L.-S., Wolf J.-E., Laurent G. Usefulness and limitations of contractile reserve evaluation in patients with low-flow, low-gradient aortic stenosis eligible for cardiac resynchronization therapy. *Eur J Heart Fail* 2014; 16: 648-654.
  52. Gonzalez J.A., Kramer C.M. Role of imaging techniques for diagnosis, prognosis and management of heart failure patients: cardiac magnetic resonance. *Curr Heart Fail Rep* 2015; 12: 276-283.
  53. Kilner P.J., Geva T., Kaemmerer H., Trindade P.T., Schwitler J., Webb G.D. Recommendations for cardiovascular magnetic resonance in adults with congenital heart disease from the respective working groups of the European Society of Cardiology. *Eur Heart J* 2010; 31: 794-805.
  54. Moon J.C., Messroghli D.R., Kellman P., Piechnik S.K., Robson M.D., Ugander M., Gatehouse P.D., Arai A.E., Friedrich M.G., Neubauer S., Schulz-Menger J., Schelbert E.B. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. *J Cardiovasc Magn Reson* 2013; 15: 92.
  55. Hundley W.G., Bluemke D.A., Finn J.P., Flamm S.D., Fogel M.A., Friedrich M.G., Ho V.B., Jerosch-Herold M., Kramer C.M., Manning W.J., Patel M., Pohost G.M., Stillman A.E., White R.D., Woodard P.K., Harrington R.A., Anderson J.L., Bates E.R., Bridges C.R., Eisenberg M.J., Ferrari V.A., Grines C.L., Hlatky M.A., Jacobs A.K., Kaul S., Lichtenberg R.C., Lindner J.R., Moliterno D.J., Mukherjee D., Rosenson R.S., Schofield R.S., Shubrooks S.J., Stein J.H., Tracy C.M., Weitz H.H., Wesley D.J. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American college of cardiology foundation task force on expert consensus documents. *Circulation* 2010; 121: 2462-2508.
  56. Yoshida A., Ishibashi-Ueda H., Yamada N., Kanzaki H., Hasegawa T., Takahama H., Amaki M., Asakura M., Kitakaze M. Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure. *Eur J Heart Fail* 2013; 15: 166-175.
  57. Bonow R.O., Castelvich S., Panza J.A., Berman D.S., Velazquez E.J., Michler R.E., She L., Holly T.A., Desvigne-Nickens P., Kosevic D., Rajda M., Chrzanowski L., Deja M., Lee K.L., White H., Oh J.K., Doenst T., Hill J.A., Rouleau J.L., Menicanti L. Severity of remodeling, myocardial viability, and survival in ischemic LV dysfunction after surgical revascularization. *JACC Cardiovasc Imaging* 2015; 8: 1121-1129.
  58. McDiarmid A.K., Loh H., Nikitin N., Cleland J.G., Ball S.G., Greenwood J.P., Plein S., Sparrow P. Predictive power of late gadolinium enhancement for myocardial recovery in chronic ischaemic heart failure: a HEART sub-study. *ESC Heart Fail* 2014; 1: 146-153.
  59. Cleland J.G.F., Calvert M., Freemantle N., Arrow Y., Ball S.G., Bonser R.S., Chattopadhyay S., Norell M.S., Pennell D.J., Senior R. The heart failure revascularization trial (HEART). *Eur J Heart Fail* 2011; 13: 227-233.
  60. Haneder S., Kucharczyk W., Schoenberg S.O., Michaely H.J. Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis. *Top Magn Reson Imaging* 2015; 24: 57-65.
  61. Beller G.A., Heede R.C. SPECT imaging for detecting coronary artery disease and determining prognosis by noninvasive assessment of myocardial perfusion and myocardial viability. *J Cardiovasc Transl Res* 2011; 4: 416-424.
  62. Gonzalez-Lopez E., Gallego-Delgado M., Guzzo-Merello G., de Haro-Del Moral F.J., Cobo-Marcos M., Robles C., Bornstein B., Salas C., Lara-Pezzi E., Alonso-Pulpon L., Garcia-Pavia P. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. *Eur Heart J* 2015; 36: 2585-2594.
  63. Beanlands R.S.B., Nichol G., Huszti E., Humen D., Racine N., Freeman M., Gulenchyn K.Y., Garrard L., de Kemp R., Guo A., Ruddy T.D., Benard F., Lamy A., Iwanochko R.M. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). *J Am Coll Cardiol* 2007; 50: 2002-2012.
  64. Larsson S.C., Orsini N., Wolk A. Alcohol consumption and risk of heart failure: a dose-response meta-analysis of prospective studies. *Eur J Heart Fail* 2015; 17: 367-373.
  65. Jolicœur E.M., Dunning A., Castelvich S., Dabrowski R., Waclawiw M.A., Petrie M.C., Stewart R., Jhund P.S., Desvigne-Nickens P., Panza J.A., Bonow R.O., Sun B., San T.R., Al-Khalidi H.R., Rouleau J.L., Velazquez E.J., Cleland J.G.F. Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction: insights from STICH. *J Am Coll Cardiol* 2015; 66: 2092-2100.
  66. Maisel A., Mueller C., Adams K., Anker S.D., Aspromonte N., Cleland J.G.F., Cohen-Solal A., Dahlstrom U., DeMaria A., DiSomma S., Filippatos G.S., Fonarow G.C., Jourdain P., Komajda M., Liu P.P., McDonagh T., McDonald K., Mebazaa A., Nieminen M.S., Peacock W.F., Tubaro M., Valle R., Vanderhyden M., Yancy C.W., Zannad F., Braunwald E. State of the art: using natriuretic peptide levels in clinical practice. *Eur J Heart Fail* 2008; 10: 824-839.
  67. Caforio A.L.P., Pankuweit S., Arbustini E., Basso C., Gimeno-Blanes J., Felix S.B., Fu M., Helio T., Heymans S., Jahns R., Klingel K., Linhart A., Maisch B., McKenna W., Mogensen J., Pinto Y.M., Ristic A., Schultheiss H.-P., Seggewiss H., Tavazzi L., Thiene G., Yilmaz A., Charron P., Elliott P.M. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J* 2013; 34: 2636-2648.
  68. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *Lancet* 2001; 357: 1385-1390.
  69. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). *N Engl J Med* 1987; 316: 1429-1435.
  70. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. *JAMA* 1995; 273: 1450-1456.
  71. Packer M., Poole-Wilson P.A., Armstrong P.W., Cleland J.G.F., Horowitz J.D., Massie B.M., Ryden L., Thygesen K., Uretsky B.F., Ryden L., Thygesen K., Uretsky B.F. ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. *Circulation* 1999; 100: 2312-2318.
  72. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med* 1991; 325: 293-302.

73. Maggioni A.P., Anker S.D., Dahlstrom U., Filippatos G., Ponikowski P., Zannad F., Amir O., Chioncel O., Leiro M.C., Drozd J., Erglis A., Fazlibeigov E., Fonseca C., Fruhwald F., Gatzov P., Goncalvesova E., Hassanein M., Hradec J., Kavaliuniene A., Lainscak M., Logeart D., Merkely B., Metra M., Persson H., Seferovic P., Temizhan A., Tousoulis D., Tavazzi L. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. *Eur J Heart Fail* 2013; 15: 1173-1184.
74. Hjalmarson A., Goldstein S., Fagerberg B., Wedel H., Waagstein F., Kjekshus J., Wikstrand J., El Allaf D., Vitovec J., Aldershvile J., Halinen M., Dietz R., Neuhaus K.L., Janosi A., Thorgeirsson G., Dunselman P.H., Gullestad L., Kuch J., Herlitz J., Rickenbacher P., Ball S., Gottlieb S., Deedwania P. MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and wellbeing in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive Heart Failure (MERIT-HF). *JAMA* 2000; 283: 1295-1302.
75. Packer M., Coats A.J., Fowler M.B., Katus H.A., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Castaigne A., Roecker E.B., Schultz M.K., DeMets D.L. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001; 344: 1651-1658.
76. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet* 1999; 353: 2001-2007.
77. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet* 1999; 353: 9-13.
78. Flather M.D., Shibata M.C., Coats A.J.S., van Veldhuisen D.J., Parkhomenko A., Borbola J., Cohen-Solal A., Dumitrascu D., Ferrari R., Lechat P., Soler-Soler J., Tavazzi L., Spinarova L., Toman J., Bohm M., Anker S.D., Thompson S.G., Poole-Wilson P.A., SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J* 2005; 26: 215-225.
79. Packer M. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. *Circulation* 2002; 106: 2194-2199.
80. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. *N Engl J Med* 1996; 334: 1349-1355.
81. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *N Engl J Med* 1999; 341: 709-717.
82. Zannad F., McMurray J.J.V., Krum H., van Veldhuisen D.J., Swedberg K., Shi H., Vincent J., Pocock S.J., Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med* 2011; 364: 11-21.
83. Faris R.F., Flather M., Purcell H., Poole-Wilson P.A., Coats A.J. Diuretics for heart failure. *Cochrane Database Syst Rev* 2012; 2: CD003838.
84. Faris R., Flather M., Purcell H., Henein J., Poole-Wilson P., Coats A. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomized controlled trials. *Int J Cardiol* 2002; 82: 149-158.
85. King J.B., Bress A.P., Reese A.D., Munger M.A. Nephrylsin inhibition in heart failure with reduced ejection fraction: a clinical review. *Pharmacother J Hum Pharmacol Drug Ther* 2015; 35: 823-837.
86. Mangiafico S., Costello-Boerrigter L.C., Andersen I.A., Cataliotti A., Burnett J.C. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. *Eur Heart J* 2013; 34: 886-893.
87. McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau J.L., Shi V.C., Solomon S.D., Swedberg K., Zile M.R., PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med* 2014; 371: 993-1004.
88. Swedberg K., Komajda M., Bohm M., Borer J.S., Ford I., Dubost-Brama A., Lerebours G., Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. *Lancet* 2010; 376: 875-885.
89. Granger C.B., McMurray J.J.V., Yusuf S., Held P., Michelson E.L., Olofsson B., Ostergren J., Pfeffer M.A., Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *Lancet* 2003; 362: 772-776.
90. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med* 2001; 345: 1667-1675.
91. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. *N Engl J Med* 1997; 336: 525-533.
92. Ouyang A.-J., Lv Y.-N., Zhong H.-L., Wen J.-H., Wei X.-H., Peng H.-W., Zhou J., Liu L.-L. Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation. *Am J Cardiol* 2015; 115: 901-906.
93. Vamos M., Erath J.W., Hohnloser S.H. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. *Eur Heart J* 2015; 36: 1831-1838.
94. van Gelder I.C., Groeneweld H.F., Crijns H.J.G.M., Tuininga Y.S., Tijssen J.G.P., Alings A.M., Hillege H.L., Bergsma-Kadijk J.A., Cornel J.H., Kamp O., Tukkie R., Bosker H.A., van Veldhuisen D.J., van den Berg M.P., RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. *N Engl J Med* 2010; 362: 1363-1373.
95. Bavishi C., Khan A.R., Ather S. Digoxin in patients with atrial fibrillation and heart failure: a meta-analysis. *Int J Cardiol* 2015; 188: 99-101.
96. Freeman J.V., Reynolds K., Fang M., Udaltsova N., Steimle A., Pomernacki N.K., Borowsky L.H., Harrison T.N., Singer D.E., Go A.S. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN Study. *Circ Arrhythmia Electrophysiol* 2015; 8: 49-58.
97. Washam J.B., Stevens S.R., Lokhnygina Y., Halperin J.L., Breithardt G., Singer D.E., Mahaffey K.W., Hankey G.J., Berkowitz S.D., Nessel C.C., Fox K.A.A., Califf R.M., Piccini J.P., Patel M.R. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). *Lancet* 2015; 385: 2363-2370.
98. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B., Castella M., Diener H.-C., Heidbuchel H., Hendriks J., Hindricks G., Manolis A.S., Oldgren J., Popescu B.A., Schotten U., Van Putte B., Vardas P., Agewall S., Camm J., Esquivas G.B., Budts W., Carerj S., Casselman F., Coca A., De Caterina R., Deftereos S., Dobrev D., Ferro J.M., Filippatos G., Fitzsimons D., Gorenek B., Guenoun M., Hohnloser S.H., Kolh P., Lip G.Y.H., Manolis A., McMurray J., Ponikowski P., Rosenhek R., Ruschitzka F., Savelieva I., Sharma S., Suwalski P., Tamargo J.L., Taylor C.J., Van Gelder I.C., Voors A.A., Windecker S., Zamorano J.L., Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *European Heart Journal* 2016; 37 (38): 2893-2962.
99. Tavazzi L., Maggioni A.P., Marchioli R., Barlera S., Franzosi M.G., Latini R., Lucci D., Nicolosi G.L., Porcu M., Tognoni G. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* 2008; 372: 1223-1230.
100. Wyse D.G., Friedman P.L., Epstein A.E. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. *N Engl J Med* 1997; 337: 1576-1583.
101. Connolly S.J., Hallstrom A.P., Cappato R., Schron E.B., Kuck K.H., Zipes D.P., Greene H.L., Boczor S., Domanski M., Follmann D., Gent M., Roberts R.S. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. *Antiarrhythmics vs Implantable Defibrillator Study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J* 2000; 21: 2071-2078.
102. Connolly S.J., Gent M., Roberts R.S., Dorian P., Roy D., Sheldon R.S., Mitchell L.B., Green M.S., Klein G.J., O'Brien B. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. *Circulation* 2000; 101: 1297-1302.
103. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. *Amiodarone Trials Meta-Analysis Investigators. Lancet* 1997; 350: 1417-1424.
104. Andrey J.L., Gomez-Soto F.M., Romero S.P., Escobar M.A., Garcia-Egido A.A., Garcia-Arjona R., Gomez F. GAMIC (Grupo para Atencion Medica Integrada de Cadiz). Mortality of newly diagnosed heart failure treated with amiodarone: a propensity-matched study. *Int J Cardiol* 2011; 151: 175-181.
105. Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau R., Domanski M., Troutman C., Anderson J., Johnson G., McNulty S.E., Clapp-Channing N., Davidson-Ray L.D., Fraulo E.S., Fishbein D.P., Luceri R.M., Ip J.H. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med* 2005; 352: 225-237.
106. Torp-Pedersen C., Metra M., Spark P., Lukas M.A., Moullet C., Scherhag A., Komajda M., Cleland J.G.F., Remme W., Di Lenarda A., Swedberg K., Poole-Wilson P.A. The safety of amiodarone in patients with heart failure. *J Card Fail* 2007; 13: 340-45.
107. Piepoli M., Villani G.Q., Ponikowski P., Wright A., Flather M.D., Coats A.J. Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure. *Int J Cardiol* 1998; 66: 1-10.
108. Chatterjee S., Ghosh J., Lichstein E., Aikat S., Mukherjee D. Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. *Am J Cardiol* 2012; 110: 607-613.
109. Kober L., Torp-Pedersen C., McMurray J.J.V., Gotzsche O., Levy S., Crijns H., Amlie J., Carlsen J. Increased mortality after dronedarone therapy for severe heart failure. *N Engl J Med* 2008; 358: 2678-2687.
110. Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obias-Manno D., Barker A.H., Arensberg D., Baker A., Friedman L., Greene H.L., Huthner M.L., Richardson D.W. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. *N Engl J Med* 1991; 324: 781-788.

- Theuns D.A.M.J., Smith T., Hunink M.G.M., Bardy G.H., Jordaens L. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. *Europace* 2010; 12: 1564-1570.
112. Cook N.R., Ridker P.M. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. *Ann Intern Med* 2009; 150: 795-802.
  113. Hohnloser S.H., Kuck K.H., Dorian P., Roberts R.S., Hampton J.R., Hatala R., Fain E., Gent M., Connolly S.J. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. *N Engl J Med* 2004; 351: 2481-2488.
  114. Steinbeck G., Andresen D., Seidl K., Brachmann J., Hoffmann E., Wojciechowski D., Kornacewicz-Jach Z, Sredniawa B., Lupkovic G., Hofgartner F., Lubinski A., Rosenqvist M., Habets A., Wegscheider K., Senges J. Defibrillator implantation early after myocardial infarction. *N Engl J Med* 2009; 361: 1427-1436.
  115. Opreanu M., Wan C., Singh V., Salehi N., Ahmad J., Szymkiewicz S.J., Thakur R.K. Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: a national database analysis. *J Heart Lung Transplant* 2015; 34: 1305-1309.
  116. Zishiri E.T., Williams S., Cronin E.M., Blackstone E.H., Ellis S.G., Roselli E.E., Smedira N.G., Gillinov A.M., Glad J.A., Tchou P.J., Szymkiewicz S.J., Chung M.K. Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. *Circ Arrhythm Electrophysiol* 2013; 6: 117-128.
  117. Chung M.K., Szymkiewicz S.J., Shao M., Zishiri E., Niebauer M.J., Lindsay B.D., Tchou P.J. Aggregate national experience with the wearable cardioverter-defibrillator. *J Am Coll Cardiol* 2010; 56: 194-203.
  118. Sanders G.D., Hlatky M.A., Owens D.K. Cost-effectiveness of implantable cardioverter-defibrillators. *N Engl J Med* 2005; 353: 1471-1480.
  119. Steinberg B.A., Al-Khatib S.M., Edwards R., Han J., Bardy G.H., Bigger J.T., Buxton A.E., Moss A.J., Lee K.L., Steinman R., Dorian P., Hallstrom A., Cappato R., Kadish A.H., Kudenchuk P.J., Mark D.B., Inoue L.Y.T., Sanders G.D. Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. *JACC Heart Fail* 2014; 2: 623-629.
  120. Raphael C.E., Finegold J.A., Barron A.J., Whinnett Z.I., Mayet J., Linde C., Cleland J.G.F., Levy W.C., Francis D.P. The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most? *Eur Heart J* 2015; 36: 1676-1688.
  121. Miller R.J.H., Howlett J.G., Exner D.V., Campbell P.M., Grant A.D.M., Wilton S.B. Baseline functional class and therapeutic efficacy of common heart failure interventions: a systematic review and meta-analysis. *Can J Cardiol* 2015; 31: 792-799.
  122. Hess P.L., Al-Khatib S.M., Han J.Y., Edwards R., Bardy G.H., Bigger J.T., Buxton A., Cappato R., Dorian P., Hallstrom A., Kadish A.H., Kudenchuk P.J., Lee K.L., Mark D.B., Moss A.J., Steinman R., Inoue L.Y.T., Sanders G. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. *Circ Cardiovasc Qual Outcomes* 2015; 8: 179-186.
  123. Stewart G.C., Weintraub J.R., Pratihbu P.P., Semigran M.J., Camuso J.M., Brooks K., Tsang S.W., Anello M.S., Nguyen V.T., Lewis E.F., Nohria A., Desai A.S., Givertz M.M., Stevenson L.W. Patient expectations from implantable defibrillators to prevent death in heart failure. *J Card Fail* 2010; 16: 106-113.
  124. Merchant F.M., Jones P., Wehrenberg S., Lloyd M.S., Saxon L.A. Incidence of defibrillator shocks after elective generator exchange following uneventful first battery life. *J Am Heart Assoc* 2014; 3: e001289.
  125. Yap S.-C., Schaefer B.A., Bhagwandien R.E., Kuhne M., Dabiri Abkenari L., Osswald S., Szili-Torok T., Sticherling C., Theuns D.A. Evaluation of the need of elective implantable cardioverter-defibrillator generator replacement in primary prevention patients without prior appropriate ICD therapy. *Heart* 2014; 100: 1188-1192.
  126. Kini V., Soufi M.K., Deo R., Epstein A.E., Bala R., Riley M., Groeneveld P.W., Shalaby A., Dixit S. Appropriateness of primary prevention implantable cardioverter-defibrillators at the time of generator replacement: are indications still met? *J Am Coll Cardiol* 2014; 63: 2388-2394.
  127. Alsheikh-Ali A.A., Homer M., Maddukuri P.V., Kalsmith B., Estes N.A.M., Link M.S. Time-dependence of appropriate implantable defibrillator therapy in patients with ischemic cardiomyopathy. *J Cardiovasc Electrophysiol* 2008; 19: 784-789.
  128. Bardy G.H., Smith W.M., Hood M.A., Crozier I.G., Melton I.C., Jordaens L., Theuns D., Park R.E., Wright D.J., Connelly D.T., Fynn S.P., Murgatroyd F.D., Sperzel J., Neuzner J., Spitzer S.G., Ardashv A.V., Oduro A., Boersma L., Maass A.H., van Gelder I.C., Wilde A.A., van Dessel P.F., Knops R.E., Barr C.S., Lupo P., Cappato R., Grace A.A. An entirely subcutaneous implantable cardioverter-defibrillator. *N Engl J Med* 2010; 363: 36-44.
  129. Aziz S., Leon A.R., El-Chami M.F. The subcutaneous defibrillator. *J Am Coll Cardiol* 2014; 63: 1473-1479.
  130. Olde Nordkamp L.R.A., Knops R.E., Bardy G.H., Blaauw Y., Boersma L.V.A., Bos J.S., Delnoy P.P.H.M., van Dessel P.F.H.M., Driessens A.H.G., de Groot J.R., Herrman J.P.R., Jordaens L.J.L.M., Kooiman K.M., Maass A.H., Meine M., Mizusawa Y., Molhoek S.G., van Opstal J., Tijssen J.G.P., Wilde A.A.M. Rationale and design of the PRAETORIAN trial: a Prospective, RAndomizEd comparison of subcutaneous and transvenous implantable cardioverter-defibrillator therapy. *Am Heart J* 2012; 163: 753-760, e2.
  131. Burke M.C., Gold M.R., Knight B.P., Barr C.S., Theuns D.A.M.J., Boersma L.V.A., Knops R.E., Weiss R., Leon A.R., Herre J.M., Husby M., Stein K.M., Lambiase P.D. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE Study and EFFORTLESS Registry. *J Am Coll Cardiol* 2015; 65: 1605-1615.
  132. Priori S.G., Blomstrom-Lundqvist C., Mazzanti A., Blom N., Borggrefe M., Camm J., Elliott P.M., Fitzsimons D., Hatala R., Hindricks G., Kirchhof P., Kjeldsen S., Kuck K.-H., Hernandez-Madrid A., Nikolaou N., Norekval T.M., Spaulding C., van Veldhuisen D.J. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology. *Eur Heart J* 2015; 36: 2793-2867.
  133. Sohaib S.M.M.A., Finegold J.A., Nijjer S.S., Hossain R., Linde C., Levy W.C., Sutton R., Kanagaratnam P., Francis D.P., Whinnett Z.I. Opportunity to increase life span in narrow QRS cardiac resynchronization therapy recipients by deactivating ventricular pacing: evidence from randomized controlled trials. *JACC Heart Fail* 2015; 3: 327-336.
  134. Cleland J.G., Abraham W.T., Linde C., Gold M.R., Young J.B., Claude Daubert J., Sherfese L., Wells G.A., Tang A.S.L. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. *Eur Heart J* 2013; 34: 3547-3556.
  135. Cleland J.G.F., Mareev Y., Linde C. Reflections on EchoCRT: sound guidance on QRS duration and morphology for CRT? *Eur Heart J* 2015; 36: 1948-1951.
  136. Woods B., Hawkins N., Mealing S., Sutton A., Abraham W.T., Beshai J.F., Klein H., Sculpher M., Plummer C.J., Cowie M.R. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. *Heart* 2015; 101: 1800-1806.
  137. Zusterzeel R., Selzman K.A., Sanders W.E., Canos D.A., O'Callaghan K.M., Carpenter J.L., Pina I.L., Strauss D.G. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data. *JAMA Intern Med* 2014; 174: 1340-1348.
  138. Linde C., Stahlberg M., Benson L., Braunschweig F., Edner M., Dahlstrom U., Alehagen U., Lund L.H. Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure. *Europace* 2015; 17: 424-431.
  139. Ruschitzka F., Abraham W.T., Singh J.P., Bax J.J., Borer J.S., Brugada J., Dickstein K., Ford I., Goresan J., Gras D., Krum H., Sogaard P., Holzmeister J. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. *N Engl J Med* 2013; 369: 1395-1405.
  140. Steffel J., Robertson M., Singh J.P., Abraham W.T., Bax J.J., Borer J.S., Dickstein K., Ford I., Goresan J., Gras D., Krum H., Sogaard P., Holzmeister J., Brugada J., Ruschitzka F. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. *Eur Heart J* 2015; 36: 1983-1989.
  141. Curtis A.B., Worley S.J., Adamson P.B., Chung E.S., Niazi I., Sherfese L., Shinn T., St John Sutton M. Biventricular pacing for atrioventricular block and systolic dysfunction. *N Engl J Med* 2013; 368: 1585-1593.
  142. Brignole M., Botto G., Mont L., Iacopino S., De Marchi G., Oddone D., Luzi M., Tolosana J.M., Navazio A., Menozzi C. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. *Eur Heart J* 2011; 32: 2420-2429.
  143. Stavrakis S., Garabelli P., Reynolds D.W. Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a meta-analysis. *Europace* 2012; 14: 1490-1497.
  144. Doshi R.N., Daoud E.G., Fellows C., Turk K., Duran A., Hamdan M.H., Pires L.A., PAVE Study Group. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). *J Cardiovasc Electrophysiol* 2005; 16: 1160-1165.
  145. Senni M., Paulus W.J., Gavazzi A., Fraser A.G., Diez J., Solomon S.D., Smiseth O.A., Guazzi M., Lam C.S.P., Maggioni A.P., Tschope C., Metra M., Hummel S.L., Edelmann F., Ambrosio G., Stewart Coats A.J., Filipatos G.S., Gheorghide M., Anker S.D., Levy D., Pfeiffer M.A., Stough W.G., Pieske B.M. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. *Eur Heart J* 2014; 35: 2797-815.
  146. Ferrari R., Bohm M., Cleland J.G.F., Paulus W.J.S., Pieske B., Rapezzi C., Tavazzi L. Heart failure with preserved ejection fraction: uncertainties and dilemmas. *Eur J Heart Fail* 2015; 17: 665-671.

147. Ather S., Chan W., Bozkurt B., Aguilar D., Ramasubbu K., Zachariah A.A., Wehrens X.H.T., Deswal A. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. *J Am Coll Cardiol* 2012; 59: 998-1005.
148. Henkel D.M., Redfield M.M., Weston S.A., Gerber Y., Roger V.L. Death in heart failure: a community perspective. *Circ Heart Fail* 2008; 1: 91-97.
149. Fukuta H., Goto T., Wakami K., Ohte N. Effects of drug and exercise intervention on functional capacity and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. *Eur J Prev Cardiol* 2016; 23: 78-85.
150. Lewis E.F., Lamas G.A., O'Meara E., Granger C.B., Dunlap M.E., McKelvie R.S., Probstfield J.L., Young J.B., Michelson E.L., Halling K., Carlsson J., Olofsson B., McMurray J.J.V., Yusuf S., Swedberg K., Pfeffer M.A. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. *Eur J Heart Fail* 2007; 9: 83-91.
151. Massie B.M., Carson P.E., McMurray J.J., Komajda M., McKelvie R., Zile M.R., Anderson S., Donovan M., Iverson E., Staiger C., Ptaszynska A. Irbesartan in patients with heart failure and preserved ejection fraction. *N Engl J Med* 2008; 359: 2456-2467.
152. Yusuf S., Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J.V., Michelson E.L., Olofsson B., Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. *Lancet* 2003; 362: 777-781.
153. Cleland J.G.F., Tendera M., Adamus J., Freemantle N., Polonski L., Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. *Eur Heart J* 2006; 27: 2338-2345.
154. Mulder B.A., van Veldhuisen D.J., Crijns H.J.G.M., Bohm M., Cohen-Solal A., Babalis D., Roughton M., Flather M.D., Coats A.J.S., van Gelder I.C. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. *Eur J Heart Fail* 2012; 14: 1171-1178.
155. van Veldhuisen D.J., Cohen-Solal A., Bohm M., Anker S.D., Babalis D., Roughton M., Coats A.J.S., Poole-Wilson P.A., Flather M.D. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction. *J Am Coll Cardiol* 2009; 53: 2150-2158.
156. Ahmed A., Rich M.W., Fleg J.L., Zile M.R., Young J.B., Kitzman D.W., Love T.E., Aronow W.S., Adams K.F., Gheorghiadu M. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. *Circulation* 2006; 114: 397-403.
157. Pitt B., Pfeffer M.A., Assmann S.F., Boineau R., Anand I.S., Claggett B., Clausell N., Desai A.S., Diaz R., Fleg J.L., Gordeev I., Harty B., Heitner J.F., Kenwood C.T., Lewis E.F., O'Meara E., Probstfield J.L., Shaburishvili T., Shah S.J., Solomon S.D., Sweitzer N.K., Yang S., McKinlay S.M. Spironolactone for heart failure with preserved ejection fraction. *N Engl J Med* 2014; 370: 1383-1392.
158. McMurray J.J.V., Ostergren J., Swedberg K., Granger C.B., Held P., Michelson E.L., Olofsson B., Yusuf S., Pfeffer M.A. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. *Lancet* 2003; 362: 767-771.
159. Beckett N.S., Peters R., Fletcher A.E., Staessen J.A., Liu L., Dumitrascu D., Stoyanovsky V., Antikainen L., Nikitin Y., Anderson C., Belhanni A., Forette F., Rajkumar C., Thijs L., Banya W., Bulpitt C.J. Treatment of hypertension in patients 80 years of age or older. *N Engl J Med* 2008; 358: 1887-1898.
160. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Bohm M., Christiaens T., Cifkova R., De Backer G., Dominiczak A., Galderisi M., Grobbee D.E., Jaarsma T., Kirchhof P., Kjeldsen S.E., Laurent S., Manolis A.J., Nilsson P.M., Ruilope L.M., Schmieder R.E., Sirtes P.A., Sleight P., Viigimaa M., Waeber B., Zannad F., Burnier M., Ambrosioni E., Caulfield M., Coca A., Olsen M.H., Tsoufis C., van de Borne P., Zamorano J.L., Achenbach S., Baumgartner H., Bax J.J., Bueno H., Dean V., Deaton C., Erol C., Ferrari R., Hasdai D., Hoes A.W., Kirchhof P., Knuuti J., Kolh P., Lancellotti P., Linhart A., Nihoyannopoulos P., Piepoli M.F., Ponikowski P., Tamargo J.L., Tendera M., Torbicki A., Wijns W., Windecker S., Clement D.L., Gillebert T.C., Rosei E.A., Ambrosioni E., Anker S.D., Bauersachs J., Hiti J.B., Caulfield M., De Buyzere M., De Geest S., Derumeaux G.A., Erdine S., Farsang C., Funck-Brentano C., Gerc V., Germano G., Gielen S., Haller H., Hoes A.W., Jordan J., Kahan T., Komajda M., Lovic D., Mahrholdt H., Ostergren J., Parati G., Perk J., Polonia J., Popescu B.A., Reiner Z., Ryden L., Sirenko Y., Stanton A., Struijker-Boudier H., Tsoufis C., Vlachopoulos C., Volpe M., Wood D.A. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J* 2013; 34: 2159-2219.
161. Sakata Y., Shiba N., Takahashi J., Miyata S., Nochioka K., Miura M., Takada T., Saga C., Shinozaki T., Sugi M., Nakagawa M., Sekiguchi N., Komaru T., Kato A., Fukuchi M., Nozaki E., Hiramoto T., Inoue K., Goto T., Ohe M., Tamaki K., Ibayashi S., Ishide N., Maruyama Y., Tsuji I., Shimokawa H. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. *Eur Heart J* 2015; 36: 915-923.
162. Ryden L., Grant P.J., Anker S.D., Berne C., Cosentino F., Danchin N., Deaton C., Escaned J., Hammes H.-P., Huikuri H., Marre M., Marx N., Mellbin L., Ostergren J., Patrono C., Seferovic P., Uva M.S., Taskiran M.-R., Tendera M., Tuomilehto J., Valensi P., Zamorano J.L., Achenbach S., Baumgartner H., Bax J.J., Bueno H., Dean V., Erol C., Fagard R., Ferrari R., Hasdai D., Hoes A.W., Kirchhof P., Knuuti J., Kolh P., Lancellotti P., Linhart A., Nihoyannopoulos P., Piepoli M.F., Ponikowski P., Sirtes P.A., Tamargo J.L., Torbicki A., Wijns W., Windecker S., De Backer G., Ezquerro E.A., Avogaro A., Badimon L., Baranova E., Betteridge J., Ceriello A., Funck-Brentano C., Gulba D.C., Kjekshus J.K., Lev E., Mueller C., Neyses L., Nilsson P.M., Perk J., Reiner Z., Sattar N., Schachinger V., Scheen A., Schirmer M., Stromberg A., Sudzhaeva S., Viigimaa M., Vlachopoulos C., Xuereb R.G. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J* 2013; 34: 3035-3087.
163. Windecker S., Kolh P., Alfonso P., Collet J.-P., Cremer J., Falk V., Filippatos G., Hamm C., Head S.J., Juni P., Kappetein A.P., Kastrati A., Knuuti J., Landmesser U., Laufer G., Neumann F.-J., Richter D.J., Schauerte P., Sousa Uva M., Stefanini G.G., Taggart D.P., Torracca L., Valgimigli M., Wijns W. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 2014; 35: 2541-2619.
164. Katriuts D.G., Siontis G.C.M., Camm A.J. Prognostic significance of ambulatory ECG monitoring for ventricular arrhythmias. *Prog Cardiovasc Dis* 2013; 56: 133-142.
165. Camm A.J., Corbucci G., Padeletti L. Usefulness of continuous electrocardiographic monitoring for atrial fibrillation. *Am J Cardiol* 2012; 110: 270-276.
166. Turakhia M.P., Ullal A.J., Hoang D.D., Than C.T., Miller J.D., Friday K.J., Perez M.V., Freeman J.V., Wang P.J., Heidenreich P.A. Feasibility of extended ambulatory electrocardiogram monitoring to identify silent atrial fibrillation in high-risk patients: the Screening Study for Undiagnosed Atrial Fibrillation (STUDY-AF). *Clin Cardiol* 2015; 38: 285-292.
167. Kirchhof P., Benussi S., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 2016. doi: 10.1093/eurheartj/ehw210. Forthcoming.
168. Camm A.J., Kirchhof P., Lip G.Y.H., Schotten U., Savelieva I., Ernst S., van Gelder I.C., Al-Attar N., Hindricks G., Prendergast B., Heidbuchel H., Alfieri O., Angelini A., Atar D., Colonna P., De Caterina R., De Sutter J., Goette A., Gorenek B., Heldal M., Hohloser S.H., Kolh P., Le Heuzey J.Y., Ponikowski P., Rutten F.H., Vahanian A., Auricchio A., Bax J.J., Ceconi C., Dean V., Filippatos G., Funck-Brentano C., Hobbs R., Kearney P., McDonagh T., Popescu B.A., Reiner Z., Sechtem U., Sirtes P.A., Tendera M., Vardas P.E., Widimsky P., Agladze V., Aliot E., Balabanski T., Blomstrom-Lundqvist C., Capucci A., Crijns H., Dahlof B., Folliguet T., Glikson M., Goethals M., Gulba D.C., Ho S.Y., Klautz R.J.M., Kose S., McMurray J., Perrone-Filardi P., Raatikainen P., Salvador M.J., Schali J.M., Shpektor A., Sousa J., Stepińska J., Uuetoa H., Zamorano J.L., Zupan I. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Eur Heart J* 2010; 31: 2369-2429.
169. Cintra F.D., Leite R.P., Storti L.J., Bittencourt L.A., Poyares D., Castro L. de S., Tufik S., Paola A. de. Sleep apnea and nocturnal cardiac arrhythmia: a population study. *Arq Bras Cardiol* 2014; 103: 368-374.
170. Gilat H., Vinker S., Buda I., Soudry E., Shani M., Bachar G. Obstructive sleep apnea and cardiovascular comorbidities: a large epidemiologic study. *Medicine (Baltimore)* 2014; 93: e45.
171. Vizzardi E., Sciatti E., Bonadei I., D'Aloia A., Curnis A., Metra M. Obstructive sleep apnoea-hypopnoea and arrhythmias. *J Cardiovasc Med* 2014; 1.
172. Bloch Thomsen P.E., Jons C., Raatikainen M.J.P., Moerch Joergensen R., Hartikainen J., Virtanen V., Boland J., Anttonen O., Gang U.J., Hoest N., Boersma L.V.A., Platou E.S., Becker D., Messier M.D., Huikuri H.V. Long-term recording of cardiac arrhythmias with an implantable cardiac monitor in patients with reduced ejection fraction after acute myocardial infarction: the Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction (CARISMA) study. *Circulation* 2010; 122: 1258-1264.
173. Faggiano P., D'Aloia A., Gualeni A., Gardini A., Giordano A. Mechanisms and immediate outcome of in-hospital cardiac arrest in patients with advanced heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. *Am J Cardiol* 2001; 87: 655-657, A10-A11.
174. Smit M.D., Moes M.L., Maass A.H., Achekar I.D., van Geel P.P., Hillege H.L., van Veldhuisen D.J., van Gelder I.C. The importance of whether atrial fibrillation or heart failure develops first. *Eur J Heart Fail* 2012; 14: 1030-1040.

- Swedberg K., Olsson L.G., Charlesworth A., Cleland J., Hanrath P., Komajda M., Metra M., Torp-Pedersen C., Poole-Wilson P. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. *Eur Heart J* 2005; 26: 1303-1308.
176. Hoppe U.C., Casares J.M., Eiskjaer H., Hagemann A., Cleland J.G.F., Freemantle N., Erdmann E. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. *Circulation* 2006; 114: 18-25.
177. Calvo N., Bisbal F., Guio E., Ramos P., Nadal M., Tolosana J.M., Arbelo E., Berrueto A., Sitges M., Brugada J., Mont L. Impact of atrial fibrillation-induced tachycardiomyopathy in patients undergoing pulmonary vein isolation. *Int J Cardiol* 2013; 168: 4093-4097.
178. Morris P.D., Robinson T., Channer K.S. Reversible heart failure: toxins, tachycardiomyopathy and mitochondrial abnormalities. *Postgrad Med J* 2012; 88: 706-712.
179. Pedersen O.D., Bagger H., Kober L., Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. *Circulation* 1999; 100: 376-380.
180. Han M., Zhang Y., Sun S., Wang Z., Wang J., Xie X., Gao M., Yin X., Hou Y. Renin-angiotensin system inhibitors prevent the recurrence of atrial fibrillation. *J Cardiovasc Pharmacol* 2013; 62: 405-415.
181. Ducharme A., Swedberg K., Pfeffer M.A., Cohen-Solal A., Granger C.B., Maggioni A.P., Michelson E.L., McMurray J.J.V., Olsson L., Rouleau J.L., Young J.B., Olofsson B., Puu M., Yusuf S. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. *Am Heart J* 2006; 152: 86-92.
182. Kotecha D., Holmes J., Krum H., Altman D.G., Manzano L., Cleland J.G.F., Lip G.Y.H., Coats A.J.S., Andersson B., Kirchhof P., von Lueder T.G., Wedel H., Rosano G., Shibata M.C., Rigby A., Flather M.D. Efficacy of beta-blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. *Lancet* 2014; 384: 2235-2243.
183. McMurray J., Kober L., Robertson M., Dargie H., Colucci W., Lopez-Sendon J., Remme W., Sharpe D.N., Ford I. Antiarrhythmic effect of carvedilol after acute myocardial infarction. *J Am Coll Cardiol* 2005; 45: 525-530.
184. Swedberg K., Zannad F., McMurray J.J.V., Krum H., van Veldhuisen D.J., Shi H., Vincent J., Pitt B. Eplerenone and atrial fibrillation in mild systolic heart failure. *J Am Coll Cardiol* 2012; 59: 1598-1603.
185. Brodsky M.A., Allen B.J., Walker C.J., Casey T.P., Luckett C.R., Henry W.L. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. *Am J Cardiol* 1987; 60: 572-575.
186. Deedwania P.C., Singh B.N., Ellenbogen K., Fisher S., Fletcher R., Singh S.N. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. *Circulation* 1998; 98: 2574-2579.
187. Shelton R.J., Clark A.L., Goode K., Rigby A.S., Houghton T., Kaye G.C., Cleland J.G.F. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: CAFE-II Study. *Heart* 2009; 95: 924-930.
188. Capucci A., Villani G.Q., Aschieri D., Rosi A., Piepoli M.F. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. *Eur Heart J* 2000; 21: 66-73.
189. Connolly S.J., Camm A.J., Halperin J.L., Joyner C., Alings M., Amerena J., Atar D., Avezum A., Blomstrom P., Borggrefe M., Budaj A., Chen S.-A., Ching C.K., Commerford P., Dans A., Davy J.-M., Delacretaz E., Di Pasquale G., Diaz R., Dorian P., Flaker G., Golitsyn S., Gonzalez-Hermosillo A., Granger C.B., Heidbuchel H., Kautzner J., Kim J.S., Lanan F., Lewis B.S., Merino J.L., Morillo C., Murin J., Narasimhan C., Paolasso E., Parkhomenko A., Peters N.S., Sim K.-H., Stiles M.K., Tanomsup S., Toivonen L., Tomcsanyi J., Torp-Pedersen C., Tse H.-F., Vardas P., Vinereanu D., Xavier D., Zhu J.-R., Baret-Cormel E., Weinling E., Staiger C., Yusuf S., Chrolavicius S., Afzal R., Hohnloser S.H. Dronedarone in high-risk permanent atrial fibrillation. *N Engl J Med* 2011; 365: 2268-2276.
190. Hofmann R., Steinwender C., Kammler J., Kypta A., Leisch F. Effects of a high dose intravenous bolus amiodarone in patients with atrial fibrillation and a rapid ventricular rate. *Int J Cardiol* 2006; 110: 27-32.
191. Hofmann R., Wimmer G., Leisch F. Intravenous amiodarone bolus immediately controls heart rate in patients with atrial fibrillation accompanied by severe congestive heart failure. *Heart* 2000; 84: 635.
192. Khand A.U., Rankin A.C., Martin W., Taylor J., Gemmell I., Cleland J.G.F. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? *J Am Coll Cardiol* 2003; 42: 1944-1951.
193. Gasparini M., Leclercq C., Lunati M., Landolina M., Auricchio A., Santini M., Boriani G., Lamp B., Proclemer A., Curnis A., Klersy C., Leyva F. Cardiac resynchronization therapy in patients with atrial fibrillation. The CERTIFY Study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). *JACC Heart Fail* 2013; 1: 500-507.
194. Roy D., Talajic M., Nattel S., Wyse D.G., Dorian P., Lee K.L., Bourassa M.G., Arnold J.M.O., Buxton A.E., Camm A.J., Connolly S.J., Dubuc M., Ducharme A., Guerra P.G., Hohnloser S.H., Lambert J., Le Heuzey J.-Y., O'Hara G., Pedersen O.D., Rouleau J.-L., Singh B.N., Stevenson L.W., Stevenson W.G., Thibault B., Waldo A.L. Rhythm control versus rate control for atrial fibrillation and heart failure. *N Engl J Med* 2008; 358: 2667-2677.
195. Ganesan A.N., Nandal S., Luker J., Pathak R.K., Mahajan R., Twomey D., Lau D.H., Sanders P. Catheter ablation of atrial fibrillation in patients with concomitant left ventricular impairment: a systematic review of efficacy and effect on ejection fraction. *Heart Lung Circ* 2015; 24: 270-280.
196. Ruff C.T., Giugliano R.P., Braunwald E., Hoffman E.B., Deenadayalu N., Ezekowitz M.D., Camm A.J., Weitz J.I., Lewis B.S., Parkhomenko A., Yamashita T., Antman E.M. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet* 2014; 383: 955-962.
197. Xiong Q., Lau Y.C., Senoo K., Lane D.A., Hong K., Lip G.Y.H. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. *Eur J Heart Fail* 2015; 17: 1192-1200.
198. Heidbuchel H., Verhamme P., Alings M., Antz M., Diener H.-C., Hacke W., Oldgren J., Sinnaeve P., Camm A.J., Kirchhof P. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. *Europace* 2015; 17: 1467-1507.
199. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., Pogue J., Reilly P.A., Themeles E., Varrone J., Wang S., Alings M., Xavier D., Zhu J., Diaz R., Lewis B.S., Darius H., Diener H.-C., Joyner C.D., Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009; 361: 1139-1151.
200. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., Breithardt G., Halperin J.L., Hankey G.J., Piccini J.P., Becker R.C., Nessel C.C., Paolini J.F., Berkowitz S.D., Fox K.A.A., Califf R.M. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med* 2011; 365: 883-891.
201. Giugliano R.P., Ruff C.T., Braunwald E., Murphy S.A., Wiviott S.D., Halperin J.L., Waldo A.L., Ezekowitz M.D., Weitz J.I., Spinar J., Ruzyllo W., Ruda M., Koretsune Y., Betcher J., Shi M., Grip L.T., Patel S.P., Patel I., Hanyok J.J., Mercuri M., Antman E.M. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2013; 369: 2093-2104.
202. Granger C.B., Alexander J.H., McMurray J.J.V., Lopes R.D., Hylek E.M., Hanna M., Al-Khalidi H.R., Ansell J., Atar D., Avezum A., Bahit M.C., Diaz R., Easton J.D., Ezekowitz J.A., Flaker G., Garcia D., Gerasides M., Gersh B.J., Golitsyn S., Goto S., Hermosillo A.G., Hohnloser S.H., Horowitz J., Mohan P., Jansky P., Lewis B.S., Lopez-Sendon J.L., Pais P., Parkhomenko A., Verheugt F.W.A., Zhu J., Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2011; 365: 981-992.
203. Connolly S.J., Eikelboom J., Joyner C., Diener H.-C., Hart R., Golitsyn S., Flaker G., Avezum A., Hohnloser S.H., Diaz R., Talajic M., Zhu J., Pais P., Budaj A., Parkhomenko A., Jansky P., Commerford P., Tan R.S., Sim K.-H., Lewis B.S., Van Mieghem W., Lip G.Y.H., Kim J.H., Lanan-Zanetti F., Gonzalez-Hermosillo A., Dans A.L., Munawar M., O'Donnell M., Lawrence J., Lewis G., Afzal R., Yusuf S. Apixaban in patients with atrial fibrillation. *N Engl J Med* 2011; 364: 806-817.
204. Holmes D.R., Doshi S.K., Kar S., Price M.J., Sanchez J.M., Sievert H., Valderrabano M., Reddy V.Y. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. *J Am Coll Cardiol* 2015; 65: 2614-2623.
205. Price M.J., Reddy V.Y., Valderrabano M., Halperin J.L., Gibson D.N., Gordon N., Huber K.C., Holmes D.R. Bleeding outcomes after left atrial appendage closure compared with long-term warfarin: a pooled, patient-level analysis of the WATCHMAN randomized trial experience. *JACC Cardiovasc Interv* 2015; 8: 1925-1932.
206. Cleland J.G., Massie B.M., Packer M. Sudden death in heart failure: vascular or electrical? *Eur J Heart Fail* 1999; 1: 41-45.
207. Desai A.S., McMurray J.J.V., Packer M., Swedberg K., Rouleau J.L., Chen F., Gong J., Rizkala A.R., Brahimi A., Claggett B., Finn P.V., Hartley L.H., Liu J., Lefkowitz M., Shi V., Zile M.R., Solomon S.D. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. *Eur Heart J* 2015; 36: 1990-1997.
208. Paulus W.J., Tschope C. A novel paradigm for heart failure with preserved ejection fraction. *J Am Coll Cardiol* 2013; 62: 263-271.
209. Marazzi G., Wajngarten M., Vitale C., Patrizi R., Pelliccia F., Gebara O., Pierri H., Ramires J.A.F., Volterrani M., Fini M., Rosano G.M.C. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease. *Int J Cardiol* 2007; 120: 79-84.
210. Vitale C., Spolietini I., Malorni W., Perrone-Filardi P., Volterrani M., Rosano G.M.C. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina – the VASCO-angina study. *Int J Cardiol* 2013; 168: 1078-1081.

211. Vitale C., Wajngaten M., Sposato B., Gebara O., Rossini P., Fini M., Volterrani M., Rosano G.M.C. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. *Eur Heart J* 2004; 25: 1814-1821.
212. Gao D., Ning N., Niu X., Hao G., Meng Z. Trimetazidine: a meta-analysis of randomized controlled trials in heart failure. *Heart* 2011; 97: 278-286.
213. Tuunanen H., Engblom E., Naum A., Nagren K., Scheinin M., Hesse B., Juhani Airaksinen K.E., Nuutila P., Iozzo P., Ukkonen H., Opie L.H., Knuuti J. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. *Circulation* 2008; 118: 1250-1258.
214. Marazzi G., Gebara O., Vitale C., Caminiti G., Wajngarten M., Volterrani M., Ramires J.A.F., Rosano G., Fini M. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy. *Adv Ther* 2009; 26: 455-461.
215. Rosano G., Vitale C., Sposato B., Mercurio G., Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. *Cardiovasc Diabetol* 2003; 2: 16.
216. Packer M., O'Connor C.M., Ghali J.K., Pressler M.L., Carson P.E., Belkin R.N., Miller A.B., Neuberger G.W., Frid D., Wertheimer J.H., Cropp A.B., DeMets D.L. Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. *N Engl J Med* 1996; 335: 1107-1114.
217. Wijeyundera H.C., Hansen M.S., Stanton E., Cropp A.S., Hall C., Dhalla N.S., Ghali J., Rouleau J.L. Neurohormones and oxidative stress in nonischemic cardiomyopathy: Relationship to survival and the effect of treatment with amlodipine. *Am Heart J* 2003; 146: 291-297.
218. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. *Lancet* 2002; 359: 1269-1275.
219. Cohn J.N., Archibald D.G., Ziesche S., Franciosa J.A., Harston W.E., Tristani F.E., Dunkman W.B., Jacobs W., Francis G.S., Flohr K.H., Goldman S., Cobb F.R., Shah P.M., Saunders R., Fletcher R.D., Loeb H.S., Hughes V.C., Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure. *N Engl J Med* 1986; 314: 1547-1552.
220. Cleland J.G., Gemmell I., Khand A., Boddy A. Is the prognosis of heart failure improving? *Eur J Heart Fail.* 1999 Aug; 1 (3): 229-41.
221. Cohn J.N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., Smith R., Dunkman W.B., Loeb H., Wong M., Bhat G., Goldman S., Fletcher R.D., Doherty J., Hughes C.V., Carson P., Cintron G., Shabetai R., Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. *N Engl J Med* 1991; 325: 303-310.
222. Goldstein R.E., Boccuzzi S.J., Cruess D., Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee and the Multicenter Diltiazem Postinfarction Research Group. *Circulation* 1991; 83: 52-60.
223. Packer M., O'Connor C.M., Ghali J.K., Pressler M.L., Carson P.E., Belkin R.N., Miller A.B., Neuberger G.W., Frid D., Wertheimer J.H., Cropp A.B., DeMets D.L. Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. *N Engl J Med* 1996; 335: 1107-1114.
224. Cohn J.N., Ziesche S., Smith R., Anand I., Dunkman W.B., Loeb H., Cintron G., Boden W., Baruch L., Rochin P., Loss L. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. *Circulation* 1997; 96: 856-863.
225. Velazquez E.J., Lee K.L., Deja M.A., Jain A., Sopko G., Marchenko A., Ali I.S., Pohost G., Gradinac S., Abraham W.T., Yui M., Prabhakaran D., Szwed H., Ferrazzi P., Petrie M.C., O'Connor C.M., Panchavinnin P., She L., Bonow R.O., Rankin G.R., Jones R.H., Rouleau J.-L. STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. *N Engl J Med* 2011; 364: 1607-1616.
226. von Haehling S., Anker S.D. Prevalence, incidence and clinical impact of cachexia: facts and numbers – update 2014. *J Cachexia Sarcopenia Muscle* 2014; 5: 261-263.
227. von Haehling S., Lainscak M., Springer J., Anker S.D. Cardiac cachexia: a systematic overview. *Pharmacol Ther* 2009; 121: 227-252.
228. Evans W.J., Morley J.E., Argiles J., Bales C., Baracos V., Guttridge D., Jatoi A., Kalantar-Zadeh K., Lochs H., Mantovani G., Marks D., Mitch W.E., Muscaritoli M., Najand A., Ponikowski P., Rossi Fanelli F., Schambelan M., Schols A., Schuster M., Thomas D., Wolfe R., Anker S.D. Cachexia: a new definition. *Clin Nutr* 2008; 27: 793-799.
229. Akashi Y.J., Springer J., Anker S.D. Cachexia in chronic heart failure: prognostic implications and novel therapeutic approaches. *Curr Heart Fail Rep* 2005; 2: 198-203.
230. Fulster S., Tacke M., Sandek A., Ebner N., Tschöpe C., Doehner W., Anker S.D., von Haehling S. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). *Eur Heart J* 2013; 34: 512-519.
231. Morley J.E., Anker S.D., von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology – update 2014. *J Cachexia Sarcopenia Muscle* 2014; 5: 253-259.
232. Piepoli M.F., Conraads V., Corra U., Dickstein K., Francis D.P., Jaarsma T., McMurray J., Pieske B., Piotrowicz E., Schmid J.-P., Anker S.D., Solal A.C., Filippatos G.S., Hoes A.W., Gielen S., Giannuzzi P., Ponikowski P.P. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. *Eur J Heart Fail* 2011; 13: 347-357.
233. von Haehling S., Anker S.D. Treatment of cachexia: an overview of recent developments. *J Am Med Dir Assoc* 2014; 15: 866-872.
234. Eschenhagen T., Force T., Ewer M.S., De Keulenaer G.W., Suter T.M., Anker S.D., Avkiran M., De Azambuja E., Balligand J.L., Brutsaert D.L., Condorelli G., Hansen A., Heymans S., Hill J.A., Hirsch E., Hilfiker-Kleiner D., Janssens S., De Jong S., Neubauer G., Pieske B., Ponikowski P., Pirmohamed M., Rauchhaus M., Sawyer D., Sugden P.H., Wojta J., Zannad F., Shah A.M. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2011; 13: 1-10.
235. Jones A.L., Barlow M., Barrett-Lee P.J., Canney P.A., Gilmour I.M., Robb S.D., Plummer C.J., Wardley A.M., Verrill M.W. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. *Br J Cancer* 2009; 100: 684-692.
236. Suter T.M., Ewer M.S. Cancer drugs and the heart: Importance and management. *Eur Heart J* 2013; 34: 1102-1111.
237. Zamorano J.-L., Lancelotti P., et al. 2016 Position paper on anticancer treatments and cardiovascular toxicity. *Eur Heart J*. 2016. doi: 10.1093/eurheartj/ehw211. Forthcoming.
238. Fan H., Yu W., Zhang Q., Cao H., Li J., Wang J., Shao Y., Hu X. Depression after heart failure and risk of cardiovascular and all-cause mortality: a meta-analysis. *Prev Med* 2014; 63: 36-42.
239. Diez-Quevedo C., Lupón J., Gonzalez B., Urrutia A., Cano L., Cabanes R., Altimir S., Coll R., Pascual T., de Antonio M., Bayes-Genis A. Depression, antidepressants, and long-term mortality in heart failure. *Int J Cardiol* 2013; 167: 1217-1225.
240. Newhouse A., Jiang W. Heart failure and depression. *Heart Fail Clin* 2014; 10: 295-304.
241. Ski C.F., Thompson D.R., Hare D.L., Stewart A.G., Watson R. Cardiac Depression Scale: Mokken scaling in heart failure patients. *Health Qual Life Outcomes* 2012; 10: 141.
242. O'Connor C.M., Jiang W., Kuchibhatla M., Silva S.G., Cuffe M.S., Callwood D.D., Zakhary B., Stough W.G., Arias R.M., Rivelli S.K., Krishnan R. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. *J Am Coll Cardiol* 2010; 56: 692-699.
243. Gilbert R.E., Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. *Lancet* 2015; 385: 2107-2117.
244. Bakris G.L., Fonseca V., Katholi R.E., McGill J.B., Messerli F.H., Phillips R.A., Raskin P., Wright J.T., Oakes R., Lukas M.A., Anderson K.M., Bell D.S.H. GEMINI Investigators for the. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. *JAMA* 2004; 292: 2227-2236.
245. Gerstein H.C., Swedberg K., Carlsson J., McMurray J.J.V., Michelson E.L., Olofsson B., Pfeffer M.A., Yusuf S. The hemoglobin A<sub>1c</sub> level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. *Arch Intern Med* 2008; 168: 1699-1704.
246. Goode K.M., John J., Rigby A.S., Kilpatrick E.S., Atkin S.L., Bragadeesh T., Clark A.L., Cleland J.G.F. Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. *Heart* 2009; 95: 917-923.
247. MacDonald M.R., Eurich D.T., Majumdar S.R., Lewsey J.D., Bhagra S., Jhund P.S., Petrie M.C., McMurray J.J.V., Petrie J.R., McAlister F.A. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. *Diabetes Care* 2010; 33: 1213-1218.
248. Boussageon R., Supper I., Bejan-Angoulvant T., Kellou N., Cucherat M., Boissel J.-P., Kassai B., Moreau A., Gueyffier F., Cornu C. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. *PLoS Med* 2012; 9: e1001204.
249. Hernandez A.V., Usmani A., Rajamanickam A., Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. *Am J Cardiovasc Drugs* 2011; 11: 115-128.
250. Komajda M., McMurray J.J.V., Beck-Nielsen H., Gomis R., Hanefeld M., Pocock S.J., Curtis P.S., Jones N.P., Home P.D. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. *Eur Heart J* 2010; 31: 824-831.



- Monami M., Dicembrini I., Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. *Nutr Metab Cardiovasc Dis* 2014; 24: 689-697.
252. Savarese G., Perrone-Filardi P., D'Amore C., Vitale C., Trimarco B., Pani L., Rosano G.M.C. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: a meta-analysis. *Int J Cardiol* 2015; 181: 239-244.
253. Zinman B., Wanner C., Lachin J.M., Fitchett D., Bluhmki E., Hantel S., Mattheus M., Devins T., Johansen O.E., Woerle H.J., Broedl U.C., Inzucchi S.E. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med* 2015; 373: 2117-2128.
254. Giagulli V.A., Moghetti P., Kaufman J.M., Guastamacchia E., Iacoviello M., Triggiani V. Managing erectile dysfunction in heart failure. *Endocr Metab Immune Disord Drug Targets* 2013; 13: 125-134.
255. Vlachopoulos C., Jackson G., Stefanadis C., Montorsi P. Erectile dysfunction in the cardiovascular patient. *Eur Heart J* 2013; 34: 2034-2046.
256. Anker S.D. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. *Circulation* 2003; 107: 1991-1997.
257. Zhang W. EULAR evidence-based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCSIT). *Ann Rheum Dis* 2006; 65: 1312-1324.
258. Doehner W., Jankowska E.A., Springer J., Lainscak M., Anker S.D. Uric acid and xanthine oxidase in heart failure – Emerging data and therapeutic implications. *Int J Cardiol*. 2015 Aug 11. pii: S0167-5273 (15) 30319-3.
259. Desai A.S. Hyperkalemia in patients with heart failure: incidence, prevalence, and management. *Curr Heart Fail Rep* 2009; 6: 272-280.
260. Kjekshus J., Apetrei E., Barrios V., Bohm M., Cleland J.G.F., Cornel J.H., Dunselman P., Fonseca C., Goudev A., Grande P., Gullestad L., Hjalmarson A., Hradec J., Janosi A., Kamensky G., Komajda M., Korewicki J., Kuusi T., Mach F., Mareev V., McMurray J.J.V., Ranjith N., Schaufelberger M., Vanhaecke J., van Veldhuisen D.J., Waagstein F., Wedel H., Wikstrand J. Rosuvastatin in older patients with systolic heart failure. *N Engl J Med* 2007; 357: 2248-2261.
261. Tavazzi L., Maggioni A.P., Marchioli R., Barlera S., Franzosi M.G., Latini R., Lucci D., Nicolosi G.L., Porcu M., Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* 2008; 372: 1231-1239.
262. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. ALLHAT Collaborative Research Group. *JAMA* 2000; 283: 1967-1975.
263. Lip G.Y.H., Skjoth F., Overvad K., Rasmussen L.H., Larsen T.B. Blood pressure and prognosis in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. *Clin Res Cardiol* 2015; 104: 1088-1096.
264. Cohn J.N., Pfeffer M.A., Rouleau J., Sharpe N., Swedberg K., Straub M., Wiltse C., Wright T.J. MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). *Eur J Heart Fail* 2003; 5: 659-667.
265. Jankowska E.A., von Haehling S., Anker S.D., Macdougall I.C., Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. *Eur Heart J* 2013; 34: 816-826.
266. Jankowska E.A., Kasztura M., Sokolski M., Bronisz M., Nawrocka S., Oleskowska-Florek W., Zymliński R., Biegus J., Siwolowski P., Banasiak W., Anker S.D., Filippatos G., Cleland J.G.F., Ponikowski P. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. *Eur Heart J* 2014; 35: 2468-2476.
267. Jankowska E.A., Malyszko J., Ardehali H., Koc-Zorawska E., Banasiak W., von Haehling S., Macdougall I.C., Weiss G., McMurray J.J.V., Anker S.D., Gheorghiadu M., Ponikowski P. Iron status in patients with chronic heart failure. *Eur Heart J* 2013; 34: 827-834.
268. Anker S.D., Comin-Colet J., Filippatos G., Willenheimer R., Dickstein K., Drexler H., Luscher T.F., Bart B., Banasiak W., Niegowska J., Kirwan B.A., Mori C., von Eisenhart Rothe B., Pocock S.J., Poole-Wilson P.A., Ponikowski P. Ferric carboxymaltose in patients with heart failure and iron deficiency. *N Engl J Med* 2009; 361: 2436-2448.
269. Ponikowski P., van Veldhuisen D.J., Comin-Colet J., Ertl G., Komajda M., Mareev V., McDonagh T., Parkhomenko A., Tavazzi L., Levesque V., Mori C., Roubert B., Filippatos G., Ruschitzka F., Anker S.D. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. *Eur Heart J* 2015; 36: 657-668.
270. Filippatos G., Farmakis D., Colet J.C., Dickstein K., Luscher T.F., Willenheimer R., Parissis J., Gaudesius G., Mori C., von Eisenhart Rothe B., Greenlaw N., Ford I., Ponikowski P., Anker S.D. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. *Eur J Heart Fail* 2013; 15: 1267-1276.
271. Jankowska E.A., Tkaczyszyn M., Suchocki T., Drozd M., von Haehling S., Doehner W., Banasiak W., Filippatos G., Anker S.D., Ponikowski P. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. *Eur J Heart Fail*. 2016 Jan 28. doi: 10.1002/ejhf.473.
272. O'Meara E., Rouleau J.L., White M., Roy K., Blondeau L., Ducharme A., Neagoe P.-E., Sirois M.G., Lavoie J., Racine N., Liszkowski M., Madore F., Tardif J.-C., de Denus S. ANCHOR Investigators. Heart failure with anemia: novel findings on the roles of renal disease, interleukins, and specific left ventricular remodeling processes. *Circ Heart Fail* 2014; 7: 773-781.
273. Swedberg K., Young J.B., Anand I.S., Cheng S., Desai A.S., Diaz R., Maggioni A.P., McMurray J.J.V., O'Connor C., Pfeffer M.A., Solomon S.D., Sun Y., Tendera M., van Veldhuisen D.J. Treatment of anemia with darbepoetin alfa in systolic heart failure. *N Engl J Med* 2013; 368: 1210-1219.
274. Damman K., Valente M.A.E., Voors A.A., O'Connor C.M., van Veldhuisen D.J., Hillege H.L. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. *Eur Heart J* 2014; 35: 455-469.
275. Filippatos G., Farmakis D., Parissis J. Renal dysfunction and heart failure: things are seldom what they seem. *Eur Heart J* 2014; 35: 416-418.
276. Damman K., Testani J.M. The kidney in heart failure: an update. *Eur Heart J* 2015; 36: 1437-1444.
277. Clark H., Krum H., Hopper I. Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction. *Eur J Heart Fail* 2014; 16: 41-48.
278. Dorszewski A., Gohmann E., Dorszewski B., Werner G.S., Kreuzer H., Figulla H.R. Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study. *J Card Fail* 1997; 3: 91-96.
279. Bayliss J., Norell M.S., Canepa-Anson R., Reid C., Poole-Wilson P., Sutton G. Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin. *Br Med J (Clin Res Ed)* 1985; 290: 1861-1865.
280. Guder G., Brenner S., Stork S., Hoes A., Rutten F.H. Chronic obstructive pulmonary disease in heart failure: accurate diagnosis and treatment. *Eur J Heart Fail* 2014; 16: 1-10.
281. Hawkins N.M., Virani S., Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. *Eur Heart J* 2013; 34: 2795-2807.
282. Kenchaiah S., Evans J.C., Levy D., Wilson P.W.F., Benjamin E.J., Larson M.G., Kannel W.B., Vasan R.S. Obesity and the risk of heart failure. *N Engl J Med* 2002; 347: 305-313.
283. Madamanchi C., Alhosaini H., Sumida A., Runge M.S. Obesity and natriuretic peptides, BNP and NT-proBNP: Mechanisms and diagnostic implications for heart failure. *Int J Cardiol* 2014; 176: 611-617.
284. McKelvie R.S., Moe G.W., Cheung A., Costigan J., Ducharme A., Estrella-Holder E., Ezekowitz J.A., Floras J., Giannetti N., Grzeslo A., Harkness K., Heckman G.A., Howlett J.G., Kouz S., Leblanc K., Mann E., O'Meara E., Rajda M., Rao V., Simon J., Swiggum E., Zieroth S., Arnold J.M.O., Ashton T., D'Astous M., Dorian P., Haddad H., Isaac D.L., Leblanc M.-H., Liu P., Sussex B., Ross H.J. The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. *Can J Cardiol* 2011; 27: 319-338.
285. Khayat R., Jarjoura D., Porter K., Sow A., Wannemacher J., Dohar R., Pleister A., Abraham W.T. Sleep disordered breathing and post-discharge mortality in patients with acute heart failure. *Eur Heart J* 2015; 36: 1463-1469.
286. Nakamura S., Asai K., Kubota Y., Murai K., Takano H., Tsukada Y.T., Shimizu W. Impact of sleep-disordered breathing and efficacy of positive airway pressure on mortality in patients with chronic heart failure and sleep-disordered breathing: a meta-analysis. *Clin Res Cardiol* 2015; 104: 208-216.
287. Bradley T.D., Logan A.G., Kimoff R.J., Series F., Morrison D., Ferguson K., Belenkie I., Pfeifer M., Fleetham J., Hanly P., Smilovitch M., Tomlinson G., Floras J.S. Continuous positive airway pressure for central sleep apnea and heart failure. *N Engl J Med* 2005; 353: 2025-2033.
288. Rahmel A., ed. Eurotransplant International Foundation Annual Report 2013. Leiden, The Netherlands: CIP-Gegevens Koninklijke Bibliotheek, 2013.
289. Trivedi J.R., Cheng A., Singh R., Williams M.L., Slaughter M.S. Survival on the heart transplant waiting list: impact of continuous flow left ventricular assist device as bridge to transplant. *Ann Thorac Surg* 2014; 98: 830-834.
290. Miller L.W., Pagani F.D., Russell S.D., John R., Boyle A.J., Aaronson K.D., Conte J.V., Naka Y., Mancini D., Delgado R.M., MacGillivray T.E., Farrar D.J., Frazier O.H. Use of a continuous-flow device in patients awaiting heart transplantation. *N Engl J Med* 2007; 357: 885-896.
291. Riebandt J., Haberl T., Mahr S., Laufer G., Rajek A., Steinlechner B., Schima H., Zimpfer D. Preoperative patient optimization using extracorporeal life support improves outcomes of INTERMACS level I patients receiving a permanent ventricular assist device. *Eur J Cardiothorac Surg* 2014; 46: 486-492.
292. Воронков Л.Г. Пациент із ХСН в Україні: аналіз усієї популяції пацієнтів, обстежених у рамках першого національного зрізового дослідження UNIVERS // Серцева недостатність. – 2012. – № 1. – С. 8-13.